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Ketodiet, physiological calcium intake and native vitamin D improve
renal osteodystrophy. The effects of a very low-protein diet (VLPD)
supplemented with amino acids and ketoanalogues (KA) and with I g of
calcium carbonate and 1000 IU of vitamin D2, were studied in 17
patients with advanced renal failure (GFR 20 mI/mm) over a period of
one year. The protein intake was 0.3 g protein/kg body wt/day. Daily
phosphorus and calcium intake were respectively 1,500 mg and 300 mg.
Sequential bone densitometry was performed and bone histomorphom-
etry after double tetracyclin labeling was evaluated, before and after
one year of diet. Calcium and phosphate metabolism parameters were
monitored every two months. In spite of a significant decrease of GFR,
phosphorus, parathyroid hormone (1-84) and osteocalcin plasma levels
decreased significantly, while low plasma bicarbonate normalized, and
calcitriol and calcium levels remained respectively low and normal.
Before the diet, histological study disclosed four cases of mixed
osteopathy: osteomalacia associated with osteitis fibrosa (OM/OF),
nine pure osteitis fibrosa (OF) and four with normal bone remodeling
(NB). After one year of diet, the OM component of OM/OF disap-
peared, as evidenced by a normalization of the mineral apposition rate
and osteoid thickness. In the patients presenting pure OF, a significant
decrease in osteoblastic and osteoclastic surfaces, in the number of
osteoclasts, and in the bone formation rate (BFR) were found. Verte-
bral mineral density measured by quantitative computerized tomoden-
sitometry did not change significantly. In conclusion, this study not
only confirms the benefical effects of VLPD + KA + calcium on uremic
hyperparathyroid bone disease in advanced renal failure assessed using
static bone histomorphometry, but also shows a correction of histody-
namic bone parameters. These results were achieved without pharma-
cological doses of vitamin D. Furthermore it suggests that: (I) the
suppression of hyperparathyroidism appears largely due to the decrease
in plasma phosphate, the correction of acidosis and the increase in 25
OH vitamin D plasma levels, independently of significant permanent
changes in plasma concentrations of calcium and calcitriol; and (2) this
diet also corrects the osteomalacic component, in spite of the absence
of a significant increase in plasma concentration of calcium and cal-
citriol, probably because of the correction of metabolic acidosis, since
the increases in mineral apposition rate and in plasma bicarbonate
levels were correlated.
Renal osteodystrophy has two main components, osteitis
fibrosa and osteomalacia, which may occur either alone or in
association (the so-called mixed osteopathy). When histologi-
cally assessed, these bone abnormalities appear quite early in
the course of renal insufficiency [1]. Preventive treatment of
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renal osteodystrophy should therefore be started early. How-
ever, its modalities are quite controversial, especially regarding
the use of vitamin D metabolites [2], although the role of the
decrease in calcitriol synthesis on stimulation of PTH synthesis
and secretion is well demonstrated [3—6]. Lack of calcitriol
stimulates PTH secretion by two mechanisms: (1) It is respon-
sible for a negative intestinal calcium balance when the diet is
poor in calcium, which tends to lower plasma calcium [7]. (2)
The calcitriol receptors of the parathyroid glands that suppress
preproPTH synthesis at the transcription level are not activated
[3].
However, administration of calcitriol in renal insufficiency
increases not only the intestinal absorption of calcium but also
that of phosphate [81 which may worsen its retention. Calcitriol
may therefore expose patients to the risk of hypercalciuria and
hypercalcemia, even at low doses in early renal failure [9], and
in spite of increasing doses of aluminum phosphate binders [10],
to the risk of hyperphosphatemia in more advanced renal
failure, causing its aggravation. The utilization of I alpha-
hydroxylated vitamin D potentiates the risk of metastatic cal-
cifications, even in children [11]. The use of aluminum phos-
phate binders induces a progressive aluminum overload which
may not only worsen the osteomalacic component of renal
osteodystrophy but also induce anemia and encephalopathy,
especially in children [12].
Therefore, other approaches to the preventive treatment of
renal osteodystrophy have been proposed mainly based on a
moderately restricted protein diet, prevention of vitamin D
depletion, and oral calcium, not only to correct the negative
intestinal calcium balance, but also to prevent phosphate reten-
tion by complexing phosphate in the gut [13]. Such a conserv-
ative treatment has been proven usually effective and safe in
uremic patients with initial GFR of 20 to 40 mI/mm [141. For
patients with more advanced renal failure (GFR < 20 mI/mm) a
diet even lower in protein supplemented with essential amino
acid and their ketoanalogues and calcium has been proposed
[15, 16]. In the study by Lucas et al [15], this treatment was able
to decrease, within three months, plasma levels of phosphate
and PTH and to increase those of plasma calcium. In Linde-
nau's study [16], the same treatment for one year in 22 patients
with maintenance of pharmacologic doses of vitamin D (20,000
to 40,000 LU per day) also induced a decrease in plasma
phosphate and PTH levels, while the static bone histomor-
phometry parameters of hyperparathyroidism improved. The
osteomalacic component of renal osteodystrophy could not be
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Table 1. Characteristics of the patients
Number of patients 17
Age years 53.5 12.5
Male 14
Female 3
Glomerular filtration rate mI/mm 13.2 4.6
Underlying nephropathy
Chronic glomerulonephritis 4
Chronic pyelonephritis 6
Polycystic kidney disease I
Benign nephrosclerosis 3
Hereditary nephritis 2
Unknown I
adequately evaluated because of the lack of double tetracyclin
bone labeling. Furthermore, calcitriol levels were not moni-
tored and the possible correction of acidosis, which plays a
major role in the pathogenesis of uremic osteomalacia [17], was
not assessed.
To adequately assess, in patients with severe renal insuffi-
ciency, the efficacy on renal osteodystrophy of a very low-
protein diet supplemented with essential amino acids, their
ketoanalogues and calcium, but without pharmacological doses
of vitamin D or physiological doses of 1-alpha hydroxylated
metabolites, and to help clarify the pathophysiological mecha-
nisms of an eventual improvement of both facets of their renal
osteodystrophy, we undertook the following study in 17 pa-
tients: evaluation of static and dynamic bone histomorphomet-
nc parameters, vertebral mineral density, as well as plasma
levels of calcium, phosphate, bicarbonate, alkaline phos-
phatase, osteocalcin, 1-84 parathyroid hormone, calcidiol and
calcitriol, before, during and after one year of this treatment.
Methods
Patients
Seventeen ambulatory patients with advanced renal failure
(GFR < 20 mI/mm) were selected for the study because of their
expected good compliance and their readiness to undergo two
sequential bone biopsies one year apart. The study was per-
formed over a one year period after approval by our Ethics
Committe. Patients with diseases known to interfere signifi-
cantly with calcium and phosphate metabolism were excluded
(those with diabetes, dysthyroidism and corticoid treatment).
Table I summarizes their clinical data. The diagnosis of renal
diseases was based upon the usual clinical, radiological and
biological investigations as well as a renal biopsy for those
suspected of having glomerulonephritis.
Design of the study
Diet mod(flcalion. Before the study all patients were already
on a somewhat restricted protein diet which was in every case
greater than 0.8 g/kg/day. Their estimated calcium intake was
817 243 mg/day. They were not taking aluminum-containing
antacids or other phosphate binders.
For the study, they were put on a very low-protein diet (0.3
g/kg) of vegetal origin (VLPD), providing 3 to 5 mg/kg/day of
phosphate and 300 mg of calcium. The caloric intake was 35
Kcal/kg/day supplied by carbohydrates for 67%, lipids for 30%
and protein for 3%. The diet was supplemented with essential
amino acids and their ketoanalogues (Ketosteril®, Fresenius,
Germany). The daily dose was one tablet for 5 kg body weight.
Each tablet provided 36 mg of nitrogen and 50 mg of calcium.
Moreover, calcium carbonate was given at a dose of I glday
(that is, 400 mg of calcium), so that the mean daily intake of
elemental calcium could be estimated at about 1,500 mg/day.
No other phosphate binder was given. All patients were also
supplemented with iron and a multivitamin preparation provid-
ing 1,000 IU of vitamin D2 per day.
Biological follow-up. Before the study and every month
thereafter, the following parameters were determined: (1) In the
urine, collected over a 24 hour period: creatinine, urea, cal-
cium, phosphate; and (2) in the plasma, while patients were
fasting: creatinine, urea, calcium, phosphate, bicarbonate, al-
kaline phosphatase, osteocalcin, intact PTH.
Before and after 12 months of diet, blood samples were
collected during the same season of the year, for calcidiol and
calcitriol determination.
The glomerular filtration rate (GFR) was evaluated every
three months based upon the clearance of 51Cr EDTA deter-
mined from plasma and urine samples.
Analytical methodology. The usual creatinine and electrolyte
determinations were performed on a Technicon® autoanalyzer.
Intact plasma PTH was measured using a two-site radioim-
munoassay [18], plasma osteocalcin by radioimmunoassay [19],
plasma calcidiol and calcitriol by competitive binding assays
[20, 21].
Bone evaluation: Bone densitometry. Dual energy quantita-
tive computerized tomodensitometry (QCT, Siemens) [22] was
performed every three months measuring cortical and trabecu-
lar mineral density of the lumbar vertebrae L2-L3-L4. The
mean value of the three vertebrae was reported.
Bone histomorphometry. After double tetracyclin labeling
(Demethylchlortetracyclin, 600 mg/day; 2 days on, 12 days off,
4 days on), a 7.5 mm transiliac trephine biopsy was obtained, at
the beginning of the study and 12 months later, thus permitting
a histodynamic evaluation of bone. Bone specimens were
embedded, without decalcification, in methyl-polymetacrylate.
Five 10 sm thick sections were stained with solochrome
cyanine for bone volume and osteoid parameter measurements.
Four sections were stained with toluidine blue for osteoblastic
measurements. Four 20 pm thick sections remained unstained,
and were examined by fluorescent microscopy for histodynamic
parameter measurements. Histomorphometric readings were
effectuated with a Zeiss ocular integrator and a semiautomated
analyzer including a digitizing table (Videoplan). Several pa-
rameters were thus measured.
(1) Static parameters.
- Trabecular bone volume (BY/TV): Percentage of bone
marrow space occupied by mineralized and unmineralized
bone.
- Trabecular osteoid volume (OV/BV): Percentage of trabec-
ular bone that is unmineralized.
- Trabecular osteoid surface (OS/BS): Percentage of trabec-
ular bone surface covered by osteoid.
- Mean osteoid thickness: (0Th) measured at equidistant
points on trabecular bone, and expressed in m.
- Osteoblastic surface (Ob.S/BS), expressed as a percentage
of the total trabecular surface (TI'S) corresponding to the
bone surface covered by active cuboid osteoblasts.
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Table 2. Evaluation of compliance to the low protein diet,
ketoanalogues, I g of calcium bicarbonate and 1000 IU of vitamin D2
Before diet After diet
Urinary urea mmol/day 238 64 65.0 25"
Urinary phosphorus mmol/day 15.4 7.3 8.6 3.6a
Urinary calcium mmoi/day 1.08 1.8 1.51 1.8
Plasma urea mmol/liter 21.7 8.5 7•7 43b
Plasma 25 OH vitamin D ng/mI 49.5 29.3 79.1 36.5a
Results are expressed as mean SD.
a p < 0.05, b P < 0.001
- Eroded surface (ES/BS): expressed as a percentage of
trabecular bone surface with resorption cavities, with or
without osteoclasts.
- Osteoclastic surface (Oc.S/BS) expressed as a percentage of
the TTS corresponding to the eroded trabecular surface
adjacent to osteoclasts.
- Number of osteoclasts per mm of trabecular surface (N.Oc/
mm) is the ratio of the number of osteoclasts per mm of
trabecular bone surface.
(2) Dynamic parameters.
- Mineral appositional rate in trabecular bone (MAR t) was
obtained by dividing the distance between the midpoints of
the two labels by the time interval between the labeling
periods (that is, 15 days) and was expressed in sm/day.
- Single-labeled surface (SL.S/BS) corresponding to the tra-
becular surface covered by a single labeling expressed as
percent of the TTS.
- Double-labeled surface (DL.S/BS) corresponding to the
trabecular surface covered by a double labeling expressed as
percent of TTS.
- Bone formation rate at the tissue level (BFR/BS), corre-
sponding to the amount of new bone mineralized per square
micrometer of trabecular bone surface area per day, was
calculated using the formula: BFRIBS = (SL.S/2 + DL.S) x
MAR t, expressed as sm3/m2/day.
The reference values are those of Rasmussen and Bordier
[23] for the static parameters and those of Vedi et al [24] for the
dynamic parameters.
(3) The bone disorders were classified as follows.
- Pure osteitis fibrosa (OF) was defined as an increase in
osteoblastic (> 8%) and osteoclastic (> 1%) surfaces without
an increase in osteoid thickness. It is characterized by a high
BFR (> 0.083 js3/2/day).
- Osteomalacia (OM) was defined by an increase in osteoid
thickness (> 10 ji) with a low BFR (< 0.02 3/s2/day).
- Mixed osteopathy (OM/OF) was defined as the association
of a low BFR, an increase in osteoid thickness (the diagnostic
criteria of OM), and the static criteria of OF (increased
osteoclastic and osteoblastic surfaces).
Bone was considered normal (NB) when the static and
dynamic parameters were within the normal range.
Statistical analysis
The differences among the groups defined by the bone
histology diagnosis at the start of the study were analyzed by
Table 3. Plasma phosphate and calcium metabolism parameters of
the whole group
Parameters
(mean SD)
Normal
range
Before the
diet
After the
diet
Calcium mmol/liter 2. 1—2.65 2.29 0.15 2.32 0.16
Phosphate mmol/iiter 0.8—1.45 1.54 0.42 1.30 0.28a
Bicarbonate mmo!/iiter 24—30 23.1 4.6 27.6 3C
Intact PTH pg/mi 10—60 168 101 83 68"
Alk. Phosphatase lU/liter 30—120 88 45 86 38
Osteocalcin pg/mi 3.7—6.9 40 29 31 25
25 OH vitamin D ng/mi 12.5—60 49.5 29.3 79.1 36.5k'
1-25 (OH)2 vitamin D pg/mi 12—32 15.3 6.8 17.5 5.9
Results are expressed as mean SD.
a p < 0.05, b p < 0.01, C P < 0.001
one-way analysis of variance. The analysis of the evolution of
the different biological parameters with time was performed by
a two-way analysis of variance (time and initial diagnosis of the
bone biopsy). The significance of correlations between the
variations in bone biopsy indexes and the variations in biolog-
ical parameters was assessed by the classical correlation coef-
ficient or by Kendall's rank correlation coefficient when a group
numbered less than nine patients. A P value less than 0.05 was
considered significant.
Results
Biological follow-up for the whole group
Clinical tolerance. All patients reported a feeling of well
being without any change in their lifestyle outside of their diet.
Their weight remained stable (66.8 12.1 kg, 65.6 11.6 kg,
N.S.).
Compliance. Compliance of most of the patients was good as
evidenced by a significant decrease in urinary excretion of urea
and phosphate, and the increase in calciuria and plasma con-
centration of calcidiol (Table 2). Only one patient was poorly
compliant, his urea excretion remaining above 200 mmollday.
Renalfunction evolu (ion. During follow-up plasma creatinine
did not change significantly (403 126 to 453 195 smol/liter,
NS), whereas EDTA clearance decreased significantly from
13.2 4.6 to 10.9 4.6 mI/mm (P < 0.02).
Calcium and phosphate metabolism parameters. Table 3
shows that after one year of VLPD, there was a significant
decrease in plasma concentrations of phosphate and P1'H, and
a significant increase in the plasma concentrations of bicarbon-
ate and 25-OH vitamin D. There was, however, no significant
change in plasma calcium, osteocalcin or alkaline phosphatase
levels which remained normal or in plasma calcitriol levels
which remained low.
Bone changes of the whole group
Bone mineral density. Table 4 shows that during the course of
the study, neither cortical nor trabecular density of the verte-
brae changed significantly.
Bone histomorphometry. The changes induced in the bone
histological pattern by VLPD after one year are depicted in
Figure 1 and Table 5.
In the four patients with mixed osteopathy, the osteomalacic
component disappeared, and the degree of osteitis fibrosa
diminished. A marked significant increase in mineral apposition
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Table 4. Changes in vertebral bone mineral density (Mean of
L2-L3-L4) for the whole group (g/cm3)
Follow-up
period
Cortical
bone
Trabecular
bone
Control 266 57 90 9
3months 258±54 87±30
6months 261±50 86±29
12 months 261 49 85 30
Results are expressed as mean SD.
rate and BFR was observed as well as a significant decrease in
osteoid thickness. Figure 2 shows a bone biopsy with two
double tetracyclin labelings performed one year apart. The
initial one, intratrabecular, performed before the diet, is merged
demonstrating the absence of bone mineralization. The second
shows two distinct labelings indicating that mineralization has
been improved.
Of the nine patients with osteitis fibrosa, four kept a milder
degree of the disorder and five improved presenting a bone
histology considered to be normal. In these patients, a signifi-
cant decrease was observed in osteoid surface, osteoblastic
surface, eroded surface, osteoclastic surface, osteoclast num-
ber, and BFR.
Of the four patients with initially normal bone, three re-
mained free of abnormalities whereas one developed severe
osteitis fibrosa. This patient was, however, the least compliant
with the diet (his urinary urea excretion remained above 200
mmol/day, whereas the others remained below 100 mmol/day).
After one year on LPD, acidosis, hyperphosphatemia and high
PTH levels were not corrected in this patient (serum concen-
trations before and after one year of diet: phosphorus 1.65 to
1.78 mmol/liter, bicarbonate 28 to 22 mmol/liter, PTH 155 to 191
pg/mI).
Plasma biochemical parameter changes according to the
initial bone histology
Figure 3 shows that plasma concentration of calcium at the
beginning of the diet was not significantly different among the
three groups, and did not significantly change during treatment.
It also shows that plasma bicarbonate concentration was lowest
in the patients with mixed osteopathy, but the difference with
the other groups was not significant. Plasma phosphate was
highest in the OF group but the difference was not significant
compared to the other groups. With the diet there was a
significant decrease in phosphate in all three groups (P < 0.05).
Plasma PTH at the beginning of the study was highest in the OF
and OM/OF groups but the difference with the normal group
was not significant. With the diet there was a significant
decrease in PTH in these two groups as well as in the group with
normal bone. It is interesting to note that the marked decrease
of PTH and phosphate during the first two months is associated
with a marked increase in plasma bicarbonate, and no increase
in plasma calcium.
Figure 4 shows a significant increase, after one year, in
plasma calcidiol but not in plasma calcitriol concentrations.
A negative correlation was found between plasma PTH
changes and plasma phosphate changes (r = 0.71;P <0.05; Fig.
5). No relationship was evidenced between changes in serum
bicarbonate levels and bone histochemical or dynamic param-
r.NBjIJLJ_OF
Fig. 1. Evolution of bone histological diagnosis after a 12 month
supplemented low-protein diet. Abbreviations are: OF, osteitis fibrosa;
OM, osteomalacia; OM/OF, mixed osteopathy; NB, normal bone.
eters, when all the patients were considered. But in the group of
patients with OM/OF, a significant positive correlation was
found between plasma bicarbonate changes and mineral appo-
sition rate changes (r = 0.95; P < 0.05; Fig. 6).
Discussion
In spite of the progression of renal insufficiency from 13.3
4.6 to 10.9 4.6 mI/mm GFR, the general good compliance of
16 out of 17 patients to a VLPD supplemented with essential
amino acids and the calcium salts of their ketoanalogues as well
as with 1 g of calcium carbonate and 1,000 IU of vitamin D2,
induced an overall improvement in their phosphocalcic distur-
bances and histologic bone abnormalities. Plasma concentra-
tions of PTH and phosphate significantly decreased whereas
plasma concentrations of calcium, calcitriol and osteocalcin did
not change significantly. Histologically, pure osteitis fibrosa
initially present in nine patients disappeared totally in five of
them and improved in four others, whereas in four patients with
mixed osteopathy, the OM component was cured in all while
the OF component was cured in two and improved in two. In
the four patients with initially normal bone, the bone remained
normal in all but one who developed a severe osteitis fibrosa.
However, this patient was noncompliant as evidenced by his
continuously high urinary urea excretion.
The improvement of hyperparathyroidism in the nine patients
with an initial histological diagnosis of OF was quite impressive
since their mean plasma PTH levels decreased from 193 115
to 95 80 pg/mI and was associated with a significant decrease
in bone remodelling as evidenced by a lower BFR, lower
osteoblastic surface and lower indexes of osteoclastic resorp-
tion. Close results have been observed in previous studies [14,
16, 25] showing an improvement of osteitis fibrosa on sequential
bone biopsies in patients with advanced renal failure who were
on a low protein diet, 0.4 to 0.8 g protein/kg/day according to
the different studies, and who were supplemented with phar-
macological doses of vitamine D and oral calcium (750 to 2,000
mg of elemental calcium).
The decrease of plasma phosphate levels with low protein
diet is explained not only by the associated decrease of phos-
phate intake, since the same nutrients provide protein and
phosphate, but also by the correction of acidosis because this
diet is poor in cystine and methionine and has therefore a low
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Table S. Bone histomorphometric changes according to the initial bone histological pattern
Fig. 2. Bone biopsy of a patient with initially mixed osteopathy.shoving two double tetracyclin labelings performed one year apart. (1) First
tetracycline labeling merged (mineral apposition rate <0.1 pii/day). (2) Second tetracycline labeling at the end of the study with two distinct
labelings showing the increase of the mineral apposition rate.
acid ash. As a matter of fact Barsotti et al [26, 27] have shown
that correction of metabolic acidosis induces a decrease in
plasma phosphate without any change in the body pool of
phosphate, probably in connection with a translocation of
phosphate from an extracellular to an intracellular site. Finally,
the oral calcium supplement in the form of calcium carbonate
(400mg of elemental calcium) and the ketoanalogues (about 700
mg of elemental calcium) can contribute to the plasma phos-
phate lowering by complexing phosphate in the gut [28—30].
The mechanism of PTH suppression in our study with VLPIi
is quite noticeable since this suppression occurred in spite of no
significant permanent increase in plasma calcium or calcitriol
levels, although transient increases in these two parameters
cannot be formally excluded. As a matter of fact a decrease in
plasma calcium has long been a well established mechanism of
the stimulation of PTH synthesis and secretion [30], the onset of
the effect on secretion being rapid (2 to 3 mm) whereas its effect
on synthesis is delayed for several hours, which is explained by
intermediary changes in transcription of the pre-pro-parathor-
mone gene. The role of plasma calcitriol in suppression of PTH
s'ynthesis [3] and secretion [4—6] is also well established. In our
study, the major explanation for the decrease of plasma PTH
levels appears to be the significant decrease of plasma phos-
phate. Although in the subgroup of nine patients with initial
Parameters
(mean SD)
OV/BV %
OS/BS %
UT p.m
Ob/BS %
ES/BS %
Oc S/BS %
N Oc/Ts mm
MAR p.m/day
BFR p.m3Ip.m2/day
Mixed
Before
osteopathyN=4
--
After
Pure osteitis fibrosa
N=9 Normal boneN=4
Before AfterBefore After
7.4 4.2
20.2 6.5
12.9 1.1
7.3 3.2
9.2 4.7
5.4 3.9
2.2 1.7
0.2 0.1
47 10
5.8 4.7
20.4 4.58±2
5.4 0.7
6.7 3.1
3.2 2.6
2.1 2
0.67 0.02
400 200
5.9 4.8
33.3 21
9.8 2.1
8.3 3.4
10.3 2.8
8 2.8
2.8 2.9
0.93 0.1
900 500
6.9 6.5
29.4 22.5k'
8.8 8.4
6.1 3.6a
6.5 23b
2.8 22b
I 0.8
0.83 0.1
440 200
Abbreviations are in the Methods section, under Static and dynamic parameters.
p < 0.05, b p < 0.01
3.4 2.9
19.1 10.9
7.8 1.7
4.2 3.1
4.8 0.9
1.2 0.2
1.03 1.3
0.7 0.05
290 250
3.5 3.7
19 15
8.4 2.5
2±1
5 2.7
1.5 1.8
0.3 0.4
0.82 0.4
300 170
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1.8
1.6
E
E 1.4
0
1.2
.
.
. .
N = 17
R = 0.71
.
P <0.05
osteitis fibrosa, the correlation between the changes in PTH
levels and the changes in phosphate levels does not reach the
level of significance, this level is achieved when the whole
group of 17 patients is considered (Fig. 5). The direct effect of
the decrease of phosphate levels on the decrease of plasma PTH
levels independently of any significant permanent change in
plasma calcium and calcitriol is quite a new concept recently
introduced by Lopez-Hilker et al [31]. From their study, the
suppressive effect of phosphate restriction on PTH secretion
had been explained on the basis of two mechanisms: (1) The
increase of plasma calcium which occurs because of a purely
physicochemical mechanism when plasma phosphate decreases
with the correction of phosphate retention [321; (2) the increase
of calcitriol plasma levels demonstrated by Llach and Massry
[33], Portale et al 134], Turner et al [351, and Tessitore et al [36]
in connection with phosphate restriction and/or phosphate
binder administration in patients with moderate renal failure
(GFR between 20 and 60 mI/mm).
In their recent article Lopez-Hilker et al [31] pointed out that
correction of hyperphosphatemia in five uremic dogs (with 5/6
nephrectomy) by phosphate intake restriction decreased plasma
PTH levels in spite of persisting low plasma calcitriol levels and
30
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Fig. 4. Serun levels of calcidiol and calcitriol before and after one
year on VLPD. Results are expressed as mean so.
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Fig. 3. Evolution of the serum levels of bicarbonate, calcium, phos-
phate and PTH under VLPD, according to the initial bone pathological
diagnosis. Symbols are: (S) mixed osteopathy; (0) Osteitis fibrosa; (•)
normal bone. Results are expressed as mean SD.
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Fig. 5. Correlation between the changes in plasma phosphate and
PTH concentrations in all patients.
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normocalcemia (the plasma calcium increase being prevented
by a lower calcium intake). Thus the direct stimulatory effect of
hyperphosphatemia on PTH secretion was clearly demon-
strated. The mechanism of this effect is not yet known, but it
has been proposed that phosphorus may potentially affect the
phospholipid composition of parathyroid cell membranes and
therefore modify calcium fluxes through the membrane or
calcitriol receptors. In patients with advanced renal failure,
phosphate restriction and/or administration of phosphate bind-
ers have usually been unable to increase plasma calcitriol
levels. Actually, a decrease in calcitriol levels was observed by
Lucas et al [15] and by Takamoto et al [37], the decrease being
explained by the decrease in plasma PTH levels [15,37] and the
possible toxic effect of aluminum on 1-alpha hydroxylase activ-
ity [37]. Only Frohling et al [38] have reported a small increase
in plasma calcitriol levels (from 25 14 to 30 12 pmol/liter) in
association with a decrease in plasma phosphate (from 5.4 to 4.4
mg/dl) and a decrease in plasma P1'H levels, in patients with
advanced renal failure treated, however, by pharmacological
doses of vitamine D2 (20,000 to 80,000 lU/day). Thus ours are
the first data in human beings demonstrating that in advanced
renal failure the effect of hyperphosphatemia correction on
PTH secretion is independent of permanent changes in plasma
concentration of calcium and calcitriol and that it can be
achieved without pharmacological doses of oral calcium or
vitamin D. In addition to the effect of hyperphosphatemia
correction on the suppression of PTH secretion, the role of
metabolic acidosis correction must be considered since, as
recently pointed out by Lefebvre et al [39], acidosis may
stimulate PTH secretion and worsen osteitis fibrosa. In fact,
plasma bicarbonate increased in our patients with initial osteitis
fibrosa from 23 to 25 mmollliter with the very low protein diet,
this alkalinizing effect of the diet being readily explained by its
low acid ash. Furthermore, since increases in plasma 25 OH
vitamin D are usually associated with an increase in 24,25(OH)2
vitamin D levels which have a mild direct suppressive effect on
pre-pro-parathormone synthesis [3], the possible role of the
significant increase observed in plasma 25 OH vitamin D levels
should also be considered.
Besides its beneficial effect on osteitis fibrosa, VLPD can
cure the OM component of renal osteodystrophy. This was
demonstrated in four patients with initial mixed osteopathy
whose increased osteoid thickness and decreased mineral ap-
position rate were normalized (Table 5) after one year of VLPD
without pharmacological doses of calcium or vitamin D, while
their normal plasma calcium concentrations remained stable
and their low plasma calcitriol concentrations did not signifi-
cantly increase. The mechanism of the beneficial effect of
VLPD on osteomalacia cannot be the decrease of plasma
phosphate since on the contrary this would favor a mineraliza-
tion defect [40, 41]. Although the total intake of elemental
calcium was about 1,500 mg and would have been sufficient to
maintain a normal calcium balance without high levels of
plasma calcitriol, it is unlikely that this phenomenon was a
major factor in the healing of osteomalacia, since plasma
calcium was initially normal in these patients (except in one)
and did not rise thereafter. The main reason was the correction
of metabolic acidosis. In the OM/OF group initial plasma
bicarbonate was low at 19 mmol/liter and increased to 24
mmollliter within two months and to 25 mmol/liter after one
year. Furthermore, changes in plasma bicarbonate were posi-
tively correlated with the changes in mineral apposition rate
(Fig. 6). A link between OM and metabolic acidosis is a well
established fact in renal osteodystrophy [17], but the causal
relationship between OM and acidosis demonstrated by the
cure of osteomalacia subsequent to correction of acidosis has
never before been reported in uremic patients as it has in
Fanconi syndrome [42, 43].
Since plasma calcidiol levels increased significantly, the role
of this increase in the reduction of osteomalacia must be
discussed, even though the beneficial effect of vitamin D on
osteomalacia depletion is explained only by the increase of
plasma concentrations of calcitriol, calcium and phosphate [44].
Nevertheless, in uremic patients it has been reported that 25
OH vitamin D3 better improved mineralization than I-alpha
(OH)2 vitamin D3 given at doses inducing a greater increase in
plasma calcium and phosphate levels [45], raising the possibility
that this metabolite, or 24-25 (OH)2 vitamin D3, which increases
when 25 OH vitamin D3 is added, may have a specific action on
mineralization. This was observed, however, for very high
doses (100 jig/day of 25 OH vitamin D3) increasing plasma
calcium levels. Therefore we do not think that the mild increase
of 25 OH vitamin D3 in our patients, which was unable to
increase plasma calcium significantly, can be responsible for the
healing of osteomalacia.
Because of the restrictive nature of the VLPD, one may
wonder about long-term effects of the diet on bone calcifica-
tion.When the individual data of all the patients are considered
after one year, PTH plasma levels are below the upper limit of
normal (60 pg/mI) in six patients and the BFR is below the lower
limit of normal (0.025 im3/m2/day) in two. This trend towards
a decrease in bone remodeling suggests that longer duration of
this regimen may promote an adynamic bone disease with its
potential risk of osteopenia [461. Therefore we sequentially
measured the vertebral mineral density by QCT. The density of
the cortical bone of the vertebrae did not change but that of
trabecular bone tended to decrease, although nonsignificantly.
This trend warrants an evaluation over a longer period of time.
Nevertheless, experience of vegetarian lifestyles in non-uremic
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Fig. 6. Correlation between the changes in plasma bicarbonate con-
centrations and the changes of the mineral apposition rate, in the four
patients with mixed osteopathy.
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patients shows that this regimen has nondeleterious effects on
bone mineral density provided calcium is adequately supple-
mented [47]. Since our patients do not develop malnutrition and
are adequately supplemented in calcium, the only potential risk
regarding their skeleton seems to be an excessive suppression
of their bone remodeling secondary to a "relative" hypopar-
athyroidism. In fact, it has been reported [48] that in dialyzed
patients 50% of those with normal plasma concentrations of
intact PTH have a histological pattern of adynamic bone.
Conclusion
In patients with advanced renal failure (GFR<20 ml/min) a
VLPD supplemented with calcium salts of ketoanalogues, 1 g of
calcium carbonate, and 1,000 IU of vitamin D2 has a favorable
effect on both components of renal osteodystrophy. The bene-
ficial effect on osteitis fibrosa is mainly explained by the
decrease of plasma PTH levels secondary to a decrease in
plasma phosphate independently of permanent changes in plasma
concentration of calcium and calcitriol, possibly in association
with the correction of acidosis and the increase in plasma 25 OH
vitamin D. The beneficial effect on osteomalacia also occurs
without significant changes in plasma calcium and calcitriol, and is
mainly explained by the correction of acidosis.
Reprint requests to Pr. M. Aparicio, Service de Nephro/ogie, Hópital
Pe/legrin, Place Amélie Raba-Léon, 33076 Bordeaux Cedex, France.
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